Evaluation of dosing strategy for pembrolizumab for oncology indications

por Freshwater, Tomoko, Kondic, Anna, Ahamadi, Malidi, Li, Claire H., de Greef, Rik, de Alwis, Dinesh, Stone, Julie A.
Publicado 2017

Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision Making

por Kondic, Anna, Bottino, Dean, Harrold, John, Kearns, Jeffrey D., Musante, CJ, Odinecs, Aleksandrs, Ramanujan, Saroja, Selimkhanov, Jangir, Schoeberl, Birgit
Publicado 2022

Immunogenicity of pembrolizumab in patients with advanced tumors

por van Vugt, Marianne J. H., Stone, Julie A., De Greef, “Rik” H. J. M. M., Snyder, Ellen S., Lipka, Leslie, Turner, David C., Chain, Anne, Lala, Mallika, Li, Mengyao, Robey, Seth H., Kondic, Anna G., De Alwis, Dinesh, Mayawala, Kapil, Jain, Lokesh, Freshwater, Tomoko
Publicado 2019

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

por Booher, Robert N., Hatch, Harold, Dolinski, Brian M., Nguyen, Thi, Harmonay, Lauren, Al-Assaad, Ali-Samer, Ayers, Mark, Nebozhyn, Michael, Loboda, Andrey, Hirsch, Heather A., Zhang, Theresa, Shi, Bin, Merkel, Carrie E., Angagaw, Minilik H., Wang, Yaolin, Long, Brian J., Lennon, Xianlu Q., Miselis, Nathan, Pucci, Vincenzo, Monahan, James W., Lee, Junghoon, Kondic, Anna Georgieva, Im, Eun Kyung, Mauro, David, Blanchard, Rebecca, Gilliland, Gary, Fawell, Stephen E., Zawel, Leigh, Schuller, Alwin G., Strack, Peter
Publicado 2014